SG11201908364YA - Cyclic plasmenylethanolamines - Google Patents
Cyclic plasmenylethanolaminesInfo
- Publication number
- SG11201908364YA SG11201908364YA SG11201908364YA SG11201908364YA SG 11201908364Y A SG11201908364Y A SG 11201908364YA SG 11201908364Y A SG11201908364Y A SG 11201908364YA SG 11201908364Y A SG11201908364Y A SG 11201908364YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cyclic
- plasmalogen
- pct
- rule
- Prior art date
Links
- 125000004122 cyclic group Chemical group 0.000 title abstract 3
- 235000009027 Amelanchier alnifolia Nutrition 0.000 abstract 2
- 244000068687 Amelanchier alnifolia Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 abstract 1
- 241000388430 Tara Species 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000003028 elevating effect Effects 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT omit IIl °nolo mu OH IIIII °min oimIE (10) International Publication Number WO 2018/191812 Al Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) of inventorship (Rule 4.17(iv)) Published: (22) International Filing Date: with international search report (Art. 21(3)) 12 March 2018 (12.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/486,037 17 April 2017 (17.04.2017) US (71) Applicant: MED-LIFE DISCOVERIES LP [CA/CA]; 104 - 407 Downey Road, Saskatoon, Saskatchewan S7N 4L8 (CA). (72) Inventor: SMITH, Tara; 351 Childers Crescent, Saska- toon, Saskatchewan S7L 4L1 (CA). (74) Agent: NEWTON, Trevor et al.; Gowling WLG (Cana- da) LLP, 160 Elgin Street, Suite 2600, Ottawa, Ontario KIP 1C3 (CA). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 1-1 ..! (54) Title: CYCLIC PLASMENYLETHANOLAMINES ei (57) : Provided herein are cyclic plasmenylethanolamines and plasmalo- 1-1 GO gen precursors of formula A, wherein R1 and R2 are each, independently, a saturat- 1-1 R R2 0 ed, unsaturated, or polyunsaturated hydrocarbon group. Methods and uses there- 1-1 0 0,11 01 1 0 of in the treatment of plasmalogen deficiency are also described. Cyclic plas- ',.. .,..„-- 1 ..., --.... ,P — N H menylethanolamines described herein may act as plasmalogen precursors which, 0 following administration, may be converted to at least one plasmalogen species, C (51) International Patent Classification: CO7F 9/6584 (2006.01) A61P 25/28 (2006.01) A61K 31/675 (2006.01) (21) International Application Number: PCT/CA2018/050291 (Formula A) thereby elevating the plasmalogen level in a subject.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762486037P | 2017-04-17 | 2017-04-17 | |
| PCT/CA2018/050291 WO2018191812A1 (en) | 2017-04-17 | 2018-03-12 | Cyclic plasmenylethanolamines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908364YA true SG11201908364YA (en) | 2019-11-28 |
Family
ID=63856201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908364Y SG11201908364YA (en) | 2017-04-17 | 2018-03-12 | Cyclic plasmenylethanolamines |
| SG10202111437XA SG10202111437XA (en) | 2017-04-17 | 2018-03-12 | Cyclic plasmenylethanolamines |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202111437XA SG10202111437XA (en) | 2017-04-17 | 2018-03-12 | Cyclic plasmenylethanolamines |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11311560B2 (en) |
| EP (1) | EP3612541A4 (en) |
| JP (2) | JP7161781B2 (en) |
| CN (1) | CN110621683B (en) |
| AU (2) | AU2018255514A1 (en) |
| CA (1) | CA3056148A1 (en) |
| SG (2) | SG11201908364YA (en) |
| WO (1) | WO2018191812A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101675337A (en) * | 2007-04-13 | 2010-03-17 | 菲诺梅诺米发现公司 | Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging |
| US20130172293A1 (en) * | 2010-09-24 | 2013-07-04 | Fujino Brain Research Co.,Ltd. | Drug against central nervous system inflammation |
| JP5997887B2 (en) * | 2011-09-05 | 2016-09-28 | 学校法人帝京大学 | Oral administration |
| CA2812178C (en) * | 2011-11-17 | 2014-11-04 | Phenomenome Discoveries Inc. | Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof |
| CA2812129C (en) * | 2011-11-17 | 2014-10-21 | Phenomenome Discoveries Inc. | Methods for the synthesis of 13c labeled plasmalogen |
| CN105646587B (en) | 2016-03-02 | 2018-03-23 | 云南中医学院 | 1,3,2 oxynitride phosphor Polymorphs alkyl compounds, preparation method and application |
-
2018
- 2018-03-12 CA CA3056148A patent/CA3056148A1/en active Pending
- 2018-03-12 EP EP18786953.2A patent/EP3612541A4/en active Pending
- 2018-03-12 CN CN201880025186.2A patent/CN110621683B/en active Active
- 2018-03-12 SG SG11201908364Y patent/SG11201908364YA/en unknown
- 2018-03-12 US US16/605,757 patent/US11311560B2/en active Active
- 2018-03-12 WO PCT/CA2018/050291 patent/WO2018191812A1/en unknown
- 2018-03-12 AU AU2018255514A patent/AU2018255514A1/en not_active Abandoned
- 2018-03-12 SG SG10202111437XA patent/SG10202111437XA/en unknown
- 2018-03-12 JP JP2019554776A patent/JP7161781B2/en active Active
-
2022
- 2022-10-07 JP JP2022162310A patent/JP2022188235A/en active Pending
- 2022-12-09 AU AU2022283770A patent/AU2022283770B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3612541A4 (en) | 2020-12-23 |
| EP3612541A1 (en) | 2020-02-26 |
| US20210128590A1 (en) | 2021-05-06 |
| WO2018191812A1 (en) | 2018-10-25 |
| AU2022283770B2 (en) | 2024-02-29 |
| CN110621683B (en) | 2023-02-17 |
| CA3056148A1 (en) | 2018-10-25 |
| CN110621683A (en) | 2019-12-27 |
| US11311560B2 (en) | 2022-04-26 |
| JP2022188235A (en) | 2022-12-20 |
| AU2022283770A1 (en) | 2023-02-02 |
| JP7161781B2 (en) | 2022-10-27 |
| JP2020516602A (en) | 2020-06-11 |
| AU2018255514A1 (en) | 2019-10-17 |
| SG10202111437XA (en) | 2021-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201907561PA (en) | Anti-lag-3 antibodies and uses thereof | |
| SG11201907056XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201805253SA (en) | Compositions and methods related to multimodal therapeutic cell systems for cancer indications | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201908675PA (en) | Computer-implemented system and method for performing transaction mixing on a blockchain | |
| SG11201811149TA (en) | METABOLIC DRUG LOADING OF EVs | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407793TA (en) | Compounds and compositions for modulating egfr activity | |
| SG11201810872UA (en) | Composition and method for reducing neutropenia | |
| SG11201407710VA (en) | Compositions comprising short-acting benzodiazepines | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201804888WA (en) | Velocity model update with an inversion gradient | |
| SG11201908472VA (en) | Compositions and methods for activating nk cells |